Most of the side effects from weight reduction surgery are moderate, although all of the cosmetics operations have some risk. According to the FDA, over 90% of patients, who had the same moderately invasive lap band surgery that Chris Christie (the New Jersey Governor) disclosed he had in February, claimed they suffered at least one side effect. Nonetheless, the US Bariatric and Metabolic Surgery Society monitors emerging weight reduction treatments; some that might eventually offer a realistic alternative to risky plastic surgery.
Some treatments, such as intragastric balloons, are promising. A balloon is inserted into the belly and blown up, to make less space for food. A couple of Brazilian studies followed over one hundred obese people who had the balloons endoscopically inserted. The studies found that, on average, patients lost 20% of their total body weight over six months. These balloons are easy to remove, and unintentional deflation appears to be the largest risk. This treatment is available in several areas of the world, however the FDA has not approved it yet for use in America.
The EndoBarrier is another weight reduction treatment the ASMBS is closely monitoring. This is a lengthy, pliable tube that resembles a plastic bag. This device affixes to the foot of the belly and negotiates its’ way through the small intestine, to ensure that food can not reach the intestine. This device uses the same principle as a gastric bypass, however it does not make permanent alterations to the anatomy of the stomach, which makes it far less risky.
In 2006, the EndoBarrier was declared safe in South America, Australia and Europe. It is predicted to be declared safe for use in America by 2017. On average, in overseas clinical tests, subjects lost 20% of their body weight in one year or less. Moreover, several subjects were able to achieve a healthy level of blood sugar and lower (or eradicate) their use of diabetes medication.
The AspireAssist Pump
The AspireAssist pump is among the more controversial gadgets on the ASMBS list of emerging technologies. This functions by extracting food straight from the belly, so that only around 33% of the calories get absorbed into the body. The twenty-four overweight subjects, who participated in the twelve-month trial of this device, lost an average of 49% of their excess body weight. This is the equivalent of around forty-five pounds. Since 2011, the AspireAssist has been available in certain European countries, such as Sweden. It is still being trialed in America, with no official word on when it might be declared safe for use.
The most recent data from the Disease Control Center puts the number of US citizens, who are obese or overweight, at almost 70%. Thus, new and innovative weight loss techniques are definitely required. It is improbable any single treatment will be effective for everyone. Therefore, it is hard to be confident that any of the above mentioned devices will become the one standard procedure to correct obesity.